Under the terms of the MOU, Physiomics will have access to the IBM supercomputer Blue C, one of the most powerful computers in the world dedicated to life sciences. This agreement, which will support Physiomics’ modelling framework and address the increasing computing requirements of system biology, is the result of a collaboration between the university, the Welsh Assembly and IBM.
The participants will set up collaborative research programs with oncology research groups at the ILS, with the first collaboration already agreed with the group of Dr Shareen Doak. These programs will focus on the effect of anticancer drugs and Physiomics will contribute with its modelling expertise in biological systems by performing simulations of mutual interest.
Dr Christophe Chassagnole, chief operating officer Physiomics, said: ‘Physiomics has continued to develop its technology to the point where more powerful computer facilities were required. The team has already run some pilot studies using the ILS Blue C supercomputer and has demonstrated its potential to reduce tasks that would take many hours to complete, to just a couple of minutes. As well the research collaborations with the ILS’ research teams will give us access to invaluable expertise and experimental data in the oncology field’.